COVID-19: NIAID VIROLOGY QUALITY ASSURANCE (VQA)
COVID-19:NIAID 病毒学质量保证 (VQA)
基本信息
- 批准号:10421161
- 负责人:
- 金额:$ 64.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-21 至 2022-06-20
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAntibodiesBiological AssayBiostatistical MethodsBritishBritish ColumbiaCOVID-19Clinical TrialsCoronavirusDataEnrollmentEnsureHIVIndividualLaboratoriesLeukapheresisMulti-site clinical studyNational Institute of Allergy and Infectious DiseaseNatural HistoryNeutralization TestsPerformancePeripheral Blood Mononuclear CellPlasmaPlasmapheresisPreparationQuality ControlReagentResearch PersonnelRunningSARS-CoV-2 B.1.1.7SARS-CoV-2 B.1.351SARS-CoV-2 infectionSARS-CoV-2 variantSamplingShipsSouth AfricaTestingTimeUniversitiesVariantpathogenic virusprogramsquality assurancerepositoryvariants of concernvirology
项目摘要
The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.
NIAID病毒学质量保证(VQA)计划的目的是为HIV和其他病毒病原体的病毒学检测提供全面的质量评估计划,这些检测是对NIAID申办的多中心临床研究中入组的受试者样本进行的。VQA计划通过为实验室提供熟练度检测组和实时检测运行质控品,并分析每个实验室的熟练度检测组和检测运行数据,确保从NIAID支持的临床试验和HIV自然史研究中获得的病毒学实验室数据的有效性和实验室间及实验室内可比性。VQA计划还实施现有和最先进的新病毒学检测的性能标准,开发和测试与检测相关的生物统计方法,并获取,测试,储存和分配质量控制材料和试剂。 该项目下的支持是SARS-CoV-2(COVID-19)病毒学检测质量保证活动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS DENNY其他文献
THOMAS DENNY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS DENNY', 18)}}的其他基金
IMMUNOLOGY QUALITY ASSESSMENT (IQA) PROGRAM
免疫学质量评估 (IQA) 计划
- 批准号:
10896891 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)
COVID-19:外部质量保证计划监督实验室 (EQAPOL)
- 批准号:
10930677 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
External Quality Assurance Program Oversight Laboratory (EQAPOL)
外部质量保证计划监督实验室 (EQAPOL)
- 批准号:
10930676 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
IMMUNOLOGY QUALITY ASSESSMENT (IQA) PROGRAM
免疫学质量评估 (IQA) 计划
- 批准号:
10653768 - 财政年份:2022
- 资助金额:
$ 64.15万 - 项目类别:
COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)
COVID-19:外部质量保证计划监督实验室 (EQAPOL)
- 批准号:
10701649 - 财政年份:2022
- 资助金额:
$ 64.15万 - 项目类别:
External Quality Assurance Program Oversight Laboratory (EQAPOL)
外部质量保证计划监督实验室 (EQAPOL)
- 批准号:
10701648 - 财政年份:2022
- 资助金额:
$ 64.15万 - 项目类别:
IMMUNOLOGY QUALITY ASSESSMENT (IQA) PROGRAM
免疫学质量评估 (IQA) 计划
- 批准号:
10439548 - 财政年份:2021
- 资助金额:
$ 64.15万 - 项目类别:
NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19
NIAID 病毒学质量保证 (VQA) COVID-19
- 批准号:
10222448 - 财政年份:2020
- 资助金额:
$ 64.15万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别: